Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Novo Nordisk (0QIU) Receives a Buy From J.P. Morgan
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Cantor Fitzgerald Raises Price Target on Novo Nordisk to $140 From $120, Keeps Overweight Rating
Novo Nordisk Analyst Ratings
Amgen Upgraded at RBC on Catalyst Setup and Growth Drivers